Britain and America have secured a major trade agreement that will maintain zero tariffs on British pharmaceutical products entering the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to boost spending on pharmaceuticals through the NHS. This move ensures that duties on these vital goods will remain at zero for a duration of 36 months.
This development follows recent warnings to dramatically increase duties on branded drug products, with increases floated up to double the cost.
"This agreement with the United Kingdom strengthens the worldwide climate for new treatments and brings much-needed balance to American-British medicine commerce," an announcement said.
Commercial Impact
Drugs constitute one of the UK's biggest export categories to the America, which is by far the largest buyer for major UK drugmakers.
Trade data reveal that in the year prior to the third quarter, the UK exported drugs valued at over eleven billion pounds to the US. This figure made up a significant portion of all goods exports in that span.
"This deal safeguards jobs, increases investment and facilitates the UK to become a international leader for biotech and pharma," a government official stated.
Specific UK Commitments
The deal entails several specific commitments from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to raise total NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage manufacturers must refund to the NHS to prevent overspending will be capped at fifteen percent. In the past, rebates exceeded twenty percent.
Industry Background
The pact follows a protracted tension between the sector and the UK government over medicine costs and approval rates.
These tensions were heightened by assertions that American customers were paying a premium for the identical medicines than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been halted or cancelled, while substantial funding commitments have been directed toward US facilities.
A senior figure acknowledged that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had decreased as a proportion of its total funding over the last ten years.
